INTRODUCTION
The majority of ARID1A mutations are mostly insertion/deletion and nonsense mutations, which lead to protein truncation and consequent rapid degradation. [1, 16] Therefore, loss of ARID1A protein expression is highly correlated with ARID1A mutation. [1, 16] Several reports have indicated the loss of ARID1A protein expression in GC and CRC. [1, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] However, clinicopathologic significances of ARID1A mutation or protein expression loss in GC and CRC patients remains unclear. [1] [2] [3] [4] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Therefore, we conducted a meta-analysis to clarify the clinicopathologic characteristics of ARID1A mutation or protein expression loss in GC and CRC patients.
MATERIAL AND METHODS

Data collection and selection criteria for meta-analysis
T he search was conducted according to the PRISMA (Preferred Reporting Items for Systemic Reviews and Meta-Analyses) guidelines. [33] We searched PubMed (http://www.ncbi.nlm.nih.gov/ pubmed) and EMBASE (www.embase.com) using the keywords: [(ARID1A) and (stomach cancer or gastric cancer) or (colorectal cancer or colon cancer or rectal cancer]. In addition, we manually explored the reference lists of identified articles. Duplicate data or overlapping articles were excluded by examining the authors' names and affiliations. When multiple articles were published by the same authors or group, the most informative or recent article was selected. Original articles reporting cases of ARID1A mutation or protein expression level in GC and CRC published before October 2016 were included. We excluded review articles without original data, conference abstracts, case reports, cell line studies, and articles lacking clinicopathologic data for meta-analysis. Geographic or language restrictions were not applied. Study quality was independently scored by two reviewers according to the Newcastle-Ottawa Scale, [34] which is frequently used for case-control studies with a maximum case-control score of 9. The selection process of the articles is shown in Figure 1 .
Data pooling and statistics
A meta-analysis was performed as previously described. [35] Briefly, effect sizes for each study were calculated by prevalence rate or odds ratio (OR) or hazard ratio (HR), and the corresponding 95% confidence interval (CI) using the Mantel-Haenszel method or the Cohen method. The prevalence rate or OR or HR was combined using a random-effects model (DerSimonian-Laird method). Statistical heterogeneity among studies was evaluated using the Cochrane Q test and I 2 statistics. The I 2 statistic refers to the percentage of variation across studies due to heterogeneity rather than chance and does not inherently depend on the number of studies considered [I 2 = 100% × (Q − df)/Q]. We clarified the cutoff of I 2 statistics for assignment of low (<25%), moderate (25-50%), and high (>50%) heterogeneities. If I 2 value was >25%, subgroup analysis was conducted. Sensitivity analyses were performed for influence of each study on the pooled prevalence rate, OR, or HR by serially omitting an individual study and pooling the remaining studies. The Publication bias was determined by funnel plots and Egger's tests for the degree of asymmetry. Publication bias was assumed as present if P value was <0.1. The pooled analysis was performed using Comprehensive Meta-analysis Software version 2.0 (Biostat, Englewood, NJ, USA).
RESULTS
Gastric cancer
ARID1A protein level
Thirteen studies reported the frequency of ARID1A protein level among 3948 cases of GC in 285 Caucasian and 3663 Asian patients [ Table 1 ]. [1, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Five [1, 17, 19, 24, 26] and four [17, 20, 24, 26] studies presented the univariate unadjusted and multivariate adjusted survival outcomes of GC patients according to the ARID1A protein level. The number of patients in each study ranged from 109 to 489, for a total of 1355 and 1316 patients, respectively. The estimated unadjusted and adjusted HRs ranged from 0.511-1.981 and 1.36-1.663, respectively. The prognostic variables used in the multivariate survival model were patient's sex, histologic type, and clinical stage. The loss of ARID1A protein expression was significantly associated with unfavorable adjusted overall HR (HR = 1.508, 95% CI: 1.249-1.820; P < 0.001, Q = 0.834, I 2 = 0.000) [ Figure 3 ], but not unadjusted overall HR (HR = 1.388, 95% CI: 0.937-2.055; P = 0.102, Q = 16.449, I 2 = 75.683). Subgroup analysis revealed that the kind of antibody used did not influence the relationship between ARID1A protein expression loss and unadjusted overall HR [ Table 2 ]. 
Score
Gastric cancer
Wang et al. [1] Hong Kong HPA005456 30/109 (27.5%) 7 Wang et al. [17] China 3H2 115/224 (51.3%) 7 Abe et al. [18] Japan HPA005456 94/857 (11.0%) 6 Yan et al. [19] China n.c. 44/183 (24.0%) 6 Wiegand et al. [20] Canada HPA005456 55/253 (21.7%) 7 Han et al. [21] Korea PSG-3 88/417 (21.1%) 7 Kim et al. [22] Korea ab171870 62/191 (32.5%) 7 Aso et al. [23] Japan HPA005456 94/468 (20.1%) 7 Kim et al. [24] Korea HPA005456 65/350 (18.6%) 7 Lee et al. [25] Korea HPA005456 22/275 (8.0%) 7 Inada et al. [26] Japan HPA005456 109/489 (22.3%) 7 Kim et al. [27] Korea HPA005456 9/100 (9.0%) 6 I-V et al. [28] Spain HPA005456 8/32 (25.0%) 7 Colorectal cancer Lee et al. [25] Korea HPA005456 12/196 (6.1%) 7 Kim et al. [27] Korea HPA005456 8/100 (8.0%) 6 Xie et al. [29] China HPA005456 26/86 (30.2%) 7 Chou et al. [30] Australia HPA005456 110/1876 (5.9%) 7 Wei et al. [31] China PSG-3 54/209 (25.8%) 7 Lee et al. [32] USA HPA005456 49/552 (8.9%) 7
Score: Newcastle-Ottawa score; nc: Not commented Figure 4 ]. Subgroup analysis revealed that the association between EBVaGC and ARID1A protein expression loss was not different according to the ethnicity and antibody type [ Table 2 ].
ARID1A mutation
A total of 10 studies reported the frequency of ARID1A mutation among 1036 GC patients, of which 551 were Caucasian and 485 were Asian [ Table 3 ]. [1] [2] [3] [4] [5] [8] [9] [10] [11] [12] Pooled analysis indicated ARID1A mutation in 16.8% of patients with GC (95% CI: 11.7-23.7). ARID1A mutation did not differ according to ethnicity (P = 0.453).
Four studies described ARID1A mutation in 325 cases with III or IV stage and 246 cases with I or II stage. Four studies reported ARID1A mutation according to the microsatellite instability (MSI). [1] [2] [3] 5] ARID1A mutation was found in 80 of 103 MSI GC cases and 55 of 422 stable MSI GC cases. ARID1A mutation was significantly associated with MSI (OR = 24.495, 95% CI: 13.633-44.012; P < 0.001, Q = 0.503, I 2 = 0.000). Three studies presented ARID1A mutation in EBVaGC. [1, 3, 4] ARID1A mutation was detected in 30 of 77 EBVaGC cases and 107 of 399 non-EBVaGC cases. ARID1A mutation was significantly associated with EBVaGC (OR = 2.572, 95% CI: 1.445-4.577; P = 0.001, Q = 0.530, I 2 = 0.000).
Colorectal cancer
Six studies reported the frequency of ARID1A protein level in 3019 CRC patients [ Table 1 ]. [25, 27, [29] [30] [31] [32] Pooled analysis indicated the loss of ARID1A protein expression in 11.7% of CRC patients (95% CI: 6.1-21.4). Five studies presented the prevalence of ARID1A mutation in 776 CRC patients [ Table 3 ]. [6] [7] [8] 13, 14] Pooled analysis indicated ARID1A mutation in 13.0% of patients with CRC (95% CI: 6.4-24.6). ARID1A mutation and protein level did not differ with ethnicity (P = 0.958 and P = 0.119, respectively).
Five studies focused on ARID1A protein level in CRC by histologic grade. [25, [29] [30] [31] [32] ARID1A protein expression loss was found in 86 of 415 poorly differentiated and 139 of 2099 well to moderately differentiated CRC Four studies reported ARID1A protein level in CRC patients according to the stage. [25, [29] [30] [31] The ARID1A protein expression loss was observed in 89 of 1118 cases with stage I, II and 112 of 1231 cases with stage III, IV CRC patients. Stage showed no significant association with ARID1A protein level (OR = 1.139, 95% CI: 0.837-1.550; P = 0.409, Q = 1.779, I 2 = 0.000).
Publication bias and sensitivity analysis
Funnel plots and the Egger's regression tests of pooled result of association between clinical stage of GC and ARID1A protein level indicated the possibility of publication bias. However, other pooled analyses showed no evidence of publication bias (data not shown).
Sensitivity analyses revealed that individual study affected the results of histologic subtype, tumor depth, stage, and unadjusted HR according to ARID1A protein level in GC. The study of Bass et al. influenced the result of EBV association. [3] However, other studies did not affect the OR or HR with the 95% CIs.
DISCUSSION
This pooled analysis using 1036 and 3948 GC patients confirmed that ARID1A mutation and ARID1A protein expression loss were detected in 17% and 27% cases, respectively. The loss of ARID1A protein expression in GC patients was significantly associated with advanced tumor depth, lymph node metastasis, and unfavorable overall survival. This meta-analysis confirmed that ARID1A mutation or protein expression loss was significantly associated with MSI and EBV infection of GC patients. In addition, the frequency of ARID1A mutation or loss of ARID1A protein expression occurred in 12-13% of CRC patients. The loss of ARID1A protein expression was significantly associated with poorly differentiated histologic grade CRC and advanced tumor depth.
To our knowledge, this is the first meta-analysis investigating the relationship between ARID1A mutation or protein expression loss and clinicopathologic parameters of GC and CRC patients. The role of ARIDA1 aberration in individual GC and CRC patient is currently unclear due to the small sample size and heterogeneous patient population. Wang et al. claimed that ARIDA1 alterations were associated with better prognosis in GC. [1] In contrast, some studies showed that loss of ARID1A protein expression was associated with poor prognostic factors. [17, 21, 22, 26] The previous published data about the associations between ARID1A alteration and clinicopathologic parameters of CRC had not been consistent. The results of pooled analysis in our study indicated that the loss of ARID1A protein expression may be a marker of poor prognosis in individual GC and CRC patient. [2] Singapore WES, S 9/110 (8.2%) 6 Bass et al. [3] USA WES 90/289 (31.1%) 7 Chen et al. [4] China WES, S 15/78 (19.2%) 7 Kim et al. [5] Korea WES 4/17 (23.5%) 6 Jones et al. [8] USA S 10/100 (10.0%) 6 Chong et al. [9] UK WES, S 7/46 (15.2%) 7 Takeshima et al. [10] Japan TS 5/50 (10.0%) 7 Ali et al. [11] USA TS 28/116 (24.1%) 7 Kuboki et al. [12] Japan TS 10/121 (8.3%) 7 Colorectal cancer Muzny et al. [6] USA WES 25/224 (11.2%) 7 Cajuso et al. [7] Finland WES 18/46 (39.1%) 7 Jones et al. [8] USA S 12/119 (10.1%) 6 Kato et al. [13] USA TS 20/347 (5.8%) 7 Ling et al. [14] China S 5/40 (12.5%) 6
Score: Newcastle-Ottawa score; WES: Whole exome sequencing; S: Sequencing; TS: Target sequencing by next generation sequencing technique
The association between ARIDA1 aberration and MSI is a very important issue. This meta-analysis revealed that ARID1A mutation causes dramatic increases in MSI GC patients. Thus, ARID1A may be a driver gene targeted by MSI pathway. Due to deficiency of data, we were unable to study the association between ARIDA1 aberration and MSI of CRC.
Our meta-analysis indicated that ARID1A mutation or loss of its protein expression in GC was associated with EBVaGC. The ARID1A mutation or protein expression loss showed approximately three-fold increase in EBVaGC compared with non-EBVaGC patients. Histologically, EBVaGC is characterized by dense lymphocytic infiltration within or surrounding GC. [36] Interestingly, the lymphoid infiltration is one of the histologic features of GC with MSI. [37] The association between ARID1A mutation or its protein expression loss and subtype with lymphocytic infiltration is suggestive that ARID1A aberration may be related to the immune surveillance of this GC subtype.
Our study had a few limitations. First, the immunohistochemical results of ARID1A protein level vary with the kind of antibody used, tissue fixation time, and data interpretation. Second, the data of ARID1A alteration according to clinicopathologic parameters were insufficient. Lastly, we roughly classified patients into Caucasian and Asian groups, which could lead to discordance between the current result and original data.
Our meta-analysis indicated that GC or CRC with ARID1A alteration might be a marker of poor prognosis. The ARID1A alteration of GC may result from different epigenetic factors.
